Summary:
Psychiatric Care and Research Center is conducting a multi-center, randomized, placebo-controlled exploratory Phase II study to examine the safety, tolerability and activity of a novel vasopressin antagonist in adults with Intermittent Explosive Disorder. Patients who have difficulty controlling verbal or physical aggression may qualify for this study.
Qualified Participants Must:
• Be between 18 and 55 years of age
•
Have episodes of impulsive verbal and/or physical aggression
•
Be in good general physical health
•
Not actively abusing substances
•
Not have a current Major Depressive Episode or have a lifetime history of Bipolar Disorder, Schizophrenia, or Organic Mental Syndrome
Qualified Participants May Receive:
Compensation for time and travel may be possible.